A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Conditions

• Psoriasis

Interventions

DRUG

HS-10374 tablets 1mg

Administered orally QD for 12 weeks

DRUG

HS-10374 tablets 5mg

Administered orally QD for 12 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 12 weeks

Sponsors & Collaborators

• Hansoh BioMedical R&D Company

  lead INDUSTRY

Principal Investigators

• Jinhua Xu · Huashan Hospital

• Yangfeng Ding · Shanghai Dermatology Hospital

• Chao Ci · First Affiliated Hospital of Wannan Medical College

• Weili Pan · Zhejiang Provincial People's Hospital

• Shiqin Tao · Wuxi No. 2 People's Hospital

• Yayu Hu · Taizhou University Affiliated Municipal Hospital

• Tianhong Xu · The Third People's Hospital of Hangzhou

• Zhu Shen · Guangdong Provincial People's Hospital

• Mingkai Ji · The Second Affiliated Hospital of Xiamen Medical College

• Chao Ji · First Affiliated Hospital of Fujian Medical University

• Qing Guo · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

• Xiaohua Wang · Dermatology Hospital of Southern Medical University

• Xiaoyong Zhou · Wuhan First Hospital

• Zudong Meng · Shiyan City People's Hospital

• Fengming Hu · Jiangxi Dermatology Hospital

• Rong Xiao · The Second Xiangya Hospital, Central South University

• Yu Wang · Affiliated Hospital of Guizhou Medical University

• Tiechi Lei · Wuhan University People's Hospital

• Yanyan Feng · Chengdu Second people's hospital

• Rixin Chen · Nanyang city first People's Hospital

• Chunshui Yu · Suining Central Hospital

• Xiaojing Kang · Xinjiang Autonomous Region People's Hospital

• Aijun Chen · First Affiliated Hospital of Chongqing Medical University

• Jianguo Li · Henan Provincial People's Hospital

• Yan Zhou · The First Affiliated Hospital of Xi 'an Jiaotong University

• Songmei Geng · The Second Affiliated Hospital of Xi 'an Jiaotong University

• Guoqiang Zhang · The First Hospital of Hebei Medical University

• Xinsuo Duan · The Affiliated Hospital of Chengde Medical College

• Linfeng li · Beijing Friendship Hospital

• Chunlei Zhang · Peking University Third Hospital

• Shifa Zhang · North East Central International Hospital Limited

• Shanshan Li · The First Hospital of Jilin University

• Yuzhen Li · The Second Affiliated Hospital of Harbin Medical University

• Xiaodong Sun · Shenyang Hospital of Integrated Chinese and Western Medicine

• Xinghua Gao · First Hospital of China Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-09-28

Primary Completion

2024-07-31

Completion

2024-08-31

Countries

• China

Study Locations